精神病學領域數位生物標記市場規模、佔有率和成長分析：按生物標記類型、資料來源、應用、使用方法、最終用戶和地區分類－2026-2033年產業預測

2024 年全球精神病學數位生物標記市場價值為 5.2 億美元，預計到 2025 年將成長至 6.318 億美元，到 2033 年將成長至 30.048 億美元，在預測期（2026-2033 年）內複合年成長率為 21.5%。

精神病學領域的數位生物標記市場涵蓋了利用智慧型手機、穿戴式裝置和雲端平台來捕捉和量化與心理健康相關的生理、行為和認知訊號的技術。該市場日益重要，因為它能夠補充傳統的臨床評估，而傳統的臨床評估往往嚴重依賴自我報告調查問卷。人們逐漸認知到，睡眠模式和語調等被動數據可能是憂鬱症發作的徵兆，這推動了創新。各公司正在發布一系列獲得FDA批准的應用程式，遠距心理健康服務的興起也增加了可遠端收集的客觀數據的需求。此外，這些服務的保險報銷機會正在推動對整合人工智慧的智慧型手機測量平台的投資，從而為歐洲和亞洲的新創公司加速進入市場和創造收入鋪平道路。

全球精神病學數位生物標記市場促進因素

臨床醫生、患者和看護者對數位化工具的日益依賴，使得精神疾病的診斷和治療策略越來越依賴生物特徵數據。這種文化轉變正在加速將客觀的數位訊號整合到標準化評估中，從而導致對檢驗的平台的需求不斷成長。隨著醫療專業人員對分析連續資料流的信心增強，他們也擴大向同儕推薦這些解決方案。這將形成一個良性循環，推動全球精神衛生機構和研究機構進一步採用這些解決方案，最終提高醫療質量，並推動精神病學領域的發展。

全球精神病學數位生物標記市場面臨的限制因素

由於資料隱私監管方面的不確定性，全球精神病學領域的數位生物標記市場面臨嚴峻挑戰。這種不確定性導致醫療服務提供者和技術開發商持謹慎態度，因為不明確的指導方針阻礙了敏感精神病生物標記數據的收集和存儲，使其難以直接合規。在缺乏標準化法規的情況下，各機構必須投入大量法律和營運資源來應對不同的區域性要求，這可能導致產品上市延遲和成本增加。這種謹慎的市場環境阻礙了對創新解決方案的投資，並將限制市場成長，直到全球範圍內建立統一的政策以確保患者資訊的安全和合乎倫理的管理。

全球精神病學數位生物標記市場趨勢

在全球精神病學領域，數位生物標記市場正經歷顯著成長，這主要得益於先進人工智慧和持續行為數據分析的融合應用。這一趨勢推動了創新平台的發展，這些平台利用語音模式、面部表情和身體活動指標來識別情緒障礙的早期徵兆。隨著臨床醫生能夠獲得動態風險評分，其關注點正從回顧性評估轉向預防性監測，從而能夠在症狀惡化之前及時干預。這種轉變不僅提高了患者的參與度，也為個人化治療策略鋪平了道路，使人工智慧驅動的預測工具成為未來精神健康保健服務的重要組成部分。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響
  • 競爭公司之間的競爭
  • 替代品的威脅
  • 買方的議價能力
  • 新進入者的威脅
  • 供應商的議價能力

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球精神病學領域數位生物標記市場規模：按生物標記類型分類

• 生理生物標記
• 行為生物標記
• 認知生物標記
• 數位表現型生物標記

全球精神病學領域數位生物標記市場規模：按資料來源分類

• 智慧型手機
• 穿戴式裝置
• 數位療法及其應用
• 其他數位資訊來源

全球精神病學數位生物標記市場規模：按應用領域分類

• 憂鬱症
• 焦慮症
• 思覺失調症
• 躁鬱症
• 其他精神疾病

全球精神病學數位生物標記市場規模：按應用領域分類

• 診斷和篩檢
• 疾病監測
• 治療反應監測
• 復發預測

全球精神病學數位生物標記市場規模：按最終用戶分類

• 醫院和診所
• 製藥和生物技術公司
• 研究機構

全球精神病學領域數位生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Koneksa Health, Inc.
• Biogen Inc.
• Empatica, Inc.
• VivoSense, Inc.
• IXICO plc
• Sonde Health, Inc.
• Clario
• Cambridge Cognition Holdings plc
• Altoida, Inc.
• Winterlight Labs Inc.
• Mindstrong Health
• Happify Health
• Pear Therapeutics, Inc.
• Akili, Inc.
• Click Therapeutics, Inc.
• Woebot Health
• Otsuka America, Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• F. Hoffmann-La Roche Ltd.

結論與建議

Global Psychiatric Digital Biomarkers Market size was valued at USD 520.0 Million in 2024 and is poised to grow from USD 631.8 Million in 2025 to USD 3000.48 Million by 2033, growing at a CAGR of 21.5% during the forecast period (2026-2033).

The market for psychiatric digital biomarkers encompasses technologies that leverage smartphones, wearables, and cloud platforms to capture and quantify physiological, behavioral, and cognitive signals relevant to mental health. This market is increasingly vital as it supplements traditional clinical assessments, often dominated by self-reported questionnaires. The recognition that passive data, like sleep patterns and voice tone, can herald depressive episodes has spurred innovation. Companies are launching FDA-cleared applications, while the rise in tele-mental health has intensified the demand for objective data that can be collected remotely. Additionally, reimbursement opportunities for these services are fostering investments in AI-integrated platforms that analyze smartphone metrics, paving the way for startups in Europe and Asia to accelerate market entry and generate revenue.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychiatric Digital Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychiatric Digital Biomarkers Market Segments Analysis

Global psychiatric digital biomarkers market is segmented by biomarker type, data source, application, use, end user and region. Based on biomarker type, the market is segmented into Physiological Biomarkers, Behavioral Biomarkers, Cognitive Biomarkers and Digital Phenotyping Biomarkers. Based on data source, the market is segmented into Smartphones, Wearable Devices, Digital Therapeutics & Applications and Other Digital Sources. Based on application, the market is segmented into Depression, Anxiety Disorders, Schizophrenia, Bipolar Disorder and Other Psychiatric Disorders. Based on use, the market is segmented into Diagnosis & Screening, Disease Monitoring, Treatment Response Monitoring and Relapse Prediction. Based on end user, the market is segmented into Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychiatric Digital Biomarkers Market

The growing embrace of digital tools by clinicians, patients, and caregivers enhances the reliance on biometric data for psychiatric diagnosis and treatment strategies. This cultural transformation promotes the integration of objective digital signals into standard assessments, leading to a rising demand for validated platforms. As healthcare professionals gain confidence in analyzing continuous data streams, they are increasingly inclined to advocate for these solutions among colleagues. This dynamic generates a positive feedback loop that propels further adoption within mental health institutions and research environments worldwide, ultimately enriching the quality of care and advancing the field of psychiatry.

Restraints in the Global Psychiatric Digital Biomarkers Market

The Global Psychiatric Digital Biomarkers market faces significant challenges due to regulatory uncertainties surrounding data privacy. These ambiguities create reluctance among providers and technology developers, as unclear guidelines hinder straightforward compliance for the collection and storage of sensitive psychiatric biomarker data. In the absence of standardized regulations, organizations are required to dedicate substantial legal and operational resources to navigate diverse regional requirements, which can lead to delays in product launches and escalated costs. This cautious landscape deters investment in innovative solutions, thereby restricting market growth until unified policies are established that ensure the secure and ethical management of patient information worldwide.

Market Trends of the Global Psychiatric Digital Biomarkers Market

The Global Psychiatric Digital Biomarkers market is experiencing significant growth driven by the integration of advanced artificial intelligence with continuous behavioral data analysis. This trend is fostering the development of innovative platforms that utilize speech patterns, facial expressions, and physical activity metrics to identify early indicators of mood disorders. As clinicians access dynamic risk scores, the focus is shifting from reactive evaluations to proactive monitoring, allowing for timely interventions before symptoms worsen. This evolution not only enhances patient engagement but also paves the way for personalized treatment strategies, positioning AI-driven predictive tools as integral components in the future of mental health care delivery.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porter's Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitutes
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Psychiatric Digital Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Physiological Biomarkers
• Behavioral Biomarkers
• Cognitive Biomarkers
• Digital Phenotyping Biomarkers

Global Psychiatric Digital Biomarkers Market Size by Data Source & CAGR (2026-2033)

• Market Overview
• Smartphones
• Wearable Devices
• Digital Therapeutics & Applications
• Other Digital Sources

Global Psychiatric Digital Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Depression
• Anxiety Disorders
• Schizophrenia
• Bipolar Disorder
• Other Psychiatric Disorders

Global Psychiatric Digital Biomarkers Market Size by Use & CAGR (2026-2033)

• Market Overview
• Diagnosis & Screening
• Disease Monitoring
• Treatment Response Monitoring
• Relapse Prediction

Global Psychiatric Digital Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Research Institutions

Global Psychiatric Digital Biomarkers Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Data Source, Application, Use, End User)
  • US
  • Canada
• Europe (Biomarker Type, Data Source, Application, Use, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Data Source, Application, Use, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Data Source, Application, Use, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Data Source, Application, Use, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Koneksa Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Empatica, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VivoSense, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IXICO plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonde Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clario
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambridge Cognition Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altoida, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Winterlight Labs Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindstrong Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Happify Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pear Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akili, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Click Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Woebot Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka America, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations